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Abstract
Objective: To describe characteristics and outcomes of HIV-infected patients with Pneumocystis jirovecii pneumonia (PCP)
over 2004–2011 in France, in particular in those previously enrolled (PE) in the French Hospital Database on HIV (FHDH).
Methods: PE patients with an incident PCP were compared with patients with an inaugural PCP revealing HIV infection
(reference). Adequate adherence to care was defined as a CD4 measurement at least every 6 months. Immune
reconstitution (CD4$200/mm3) and risk of death were studied using Kaplan-Meier estimates and multivariable Cox
proportional hazards models.
Results: In a context of a decreasing incidence of PCP, 1259 HIV-infected patients had a PCP diagnosis, and 593 (47%) were
PE patients of whom 161 (27%) have had a prior history of AIDS-defining clinical illness (prior ADI). Median time since
enrolment was 8 years for PE patients; 74% had received cART. Median proportion of time with adequate adherence to care
was 85% (IQR, 66–96) for all FHDH enrollees, but only 45% (IQR, 1–81) for PE patients during the 2 years before PCP. Median
CD4 cell count (38/mm3) and HIV viral load (5.2 log10 copies/ml) at PCP diagnosis did not differ between PE patients and
the reference group. Three year mortality rate of 25% was observed for PE prior ADI group, higher than in PE non-prior ADI
group (8%) and the reference group (9%) (p,0.0001). In the PE prior ADI group, poor prognosis remained even after
adjustment for virological control and immune reconstitution (HR, 2.4 [95%CI, 1.5–3.7]).
Conclusion: Almost 50% of PCP diagnoses in HIV-infected patients occurred presently in patients already in care, mainly
with a previous cART prescription but with waning adherence to care. Having repeated ADI is contributing to the risk of
death beyond its impact on immune reconstitution and viral suppression: special efforts must be undertaken to maintain
those patients in care.
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Introduction
Pneumocystis jirovecii pneumonia (PCP) is a well-recognized major
opportunistic infection and one of the most common AIDS-
defining illnesses (ADI) [1–3]. Before the introduction of
Pneumocystis prophylaxis and combination antiretroviral therapy
(cART), it was estimated that 75% of HIV infected patients
developed PCP during their lifetime [3,4]. After 1996, with the
availability of cART, a dramatic decline in PCP incidence was
observed in HIV infected patients [5]. In previous studies, the
proportion of PCP diagnoses that revealed HIV infection ranged
from 23% to 55%, while none or few patients with a previously
known HIV diagnosis were under cART [6–8].
In industrialized countries, fewer than 10% of patients taking
cART experience virological failure [9]. In 2011, 82% of HIV-
infected patients enrolled in the FHDH cohort had been on cART
for at least 6 months, and 89% of them had a viral load (VL) below
50 copies/ml [10]. Therefore, the risk of presenting a PCP should
be limited to basically late presenters. However, retention in care is
an emerging problem: a meta-analysis conducted between 1995
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and 2009 in the United States showed that only 59% of patients
regularly attended medical appointments [11]. In 2013, some
authors reported that half of the patients presenting with an ADI
[12,13] and specifically PCP [12,13] were already in care. This
raises concerns about long-term adherence to care and its
repercussion on morbidity and mortality. Here we studied the
characteristics and outcome of patients who presented a PCP
diagnosis while already in care with or without a prior ADI and
compared them with late presenter patients with an inaugural PCP
during 2004–2011 in France. In particular the role of repetitive
ADI on risk of mortality was investigated.
Patients and Methods
Patients
The French Hospital Database on HIV (FHDH) is a nationwide
hospital-based cohort [14].This epidemiological network was
created in 1989. Seventy participating hospitals across France
provide data on HIV-infected patients, who represent 50–60% of
all HIV-seropositive patients receiving care in France. The only
FHDH inclusion criteria are HIV-1 or HIV-2 infection and
written informed consent. Trained research assistants prospective-
ly collect clinical, biological and therapeutic data and causes of
death from medical records, using specialized software. For this
analysis, we considered all HIV-1-infected patients enrolled in the
FHDH who had a first diagnosis of PCP. PCP diagnosis was
considered definitive if there was a histologic or cytologic evidence
of P. jirovecii on bronchoalveolar lavage, sputum and/or lung
biopsy specimens. Diagnosis was considered only presumptive if
there was a recent history of dyspnea or nonproductive cough in
the absence of evidence of bacterial pneumonia, and a positive
clinical response to appropriate therapy for PCP. We excluded
patients with no CD4 cell count within 3 months of PCP diagnosis
and surviving patients with no CD4 cell count after PCP. Patients
previously enrolled (PE) in the FHDH with an incident PCP were
compared to patients with a PCP revealing HIV infection (taken as
the reference group). The group of PE patients was divided into
patients with a prior history of AIDS-defining illness (ADI) (PE
prior ADI) and those without prior ADI (PE non prior ADI). ADI
was defined as a C category according to the 1993 CDC criteria.
Definition of adequate adherence to care
Adherence to care of patients enrolled in FHDH was considered
adequate if they had a CD4 cell count at least every 6 months. The
duration of adequate adherence to care was calculated as the sum
of the number of days between two CD4 cell counts, after
excluding days exceeding the time window of 6 months. For
patients with no CD4 cell counts prior to PCP, the duration of
adequate adherence to care were set at 0. The proportion of time
spent with adequate adherence to care was determined by dividing
the number of days with adequate adherence to care by the total
length of follow up. This indicator of adherence to care was
calculated for each patient with at least a visit in the period 2004–
2011 and who were followed up for at least 3 years in the FHDH
cohort. For PE with an incident PCP, adherence to care was first
calculated from the first visit (enrolment in the FHDH) until PCP
diagnosis; then adherence to care was calculated during the last 2
years before PCP. In the whole cohort, adherence to care was
calculated from the first visit (enrolment in the FHDH) until the
last one in the FHDH cohort.
Statistical analysis
Incidence of PCP among PE patients was calculated for each
year during the study period by dividing the number of PE PCP
cases by the number of person-years followed during that year in
the cohort. Frequency of inaugural PCP among newly enrolled
patients was calculated for each year during the study period by
dividing the number of PCP cases in the reference group by the
number of new patients included in the cohort during the same
year. Evolution of the proportion of PCP diagnosis in PE patients
during the study period was compared by a Cochran Armitage test
for trend.
Baseline characteristics were compared across the 3 groups, PE
prior ADI, PE non-prior ADI and patients with a PCP revealing
HIV infection (reference group) by using the x2 test for categorical
variables and the Kruskal-Wallis test for continuous variables.
Kaplan-Meier estimates of the proportion of patients with
virological control (HIV viral load [VL]#50 copies/ml), the
proportion of patients with immune reconstitution (CD4.200/
mm3), and survival were compared between the three groups of
patients after right censoring the data 3 years after PCP diagnosis.
Cox proportional hazards models were used to identify factors
associated with outcome, including age (,30 years, $30 to ,50,
and $50), country of origin (sub-Saharan Africa, others), the HIV
exposure category (men who have sex with men (MSM),
intravenous drug users (IDU), heterosexual), CD4 cell counts at
PCP diagnosis (CD4,50/mm3, 50#CD4,100, 100#CD4,200,
CD4$200), and HIV viral load at PCP diagnosis (VL,5 log
copies/ml, VL$5 log copies/ml). In the Cox model for immune
reconstitution, virological control was included as time-dependent
variable. In the Cox model for mortality, virological control and
immune reconstitution were included as time-dependent variables.
All tests were two-sided, and P values below 0.05 were
considered to denote statistical significance. All statistical analyses
used the SAS software package (version 9.3; SAS Institute, Cary,
NC, USA).
Figure 1. Trends in the risk of PCP overtime: incidence of first
PCP for previously enrolled patients (bolt line) and frequency
of inaugural PCP in newly enrolled patients (dotted line).
doi:10.1371/journal.pone.0094183.g001
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Results
Trends of PCP over time
Over the period 2004–2011, 85,743 patients had a follow-up in
the FHDH and 35,985 new patients were included in the FHDH
cohort. There was a decreasing frequency of PCP in the group of
patients with an inaugural PCP and a decreasing incidence of PCP
for previously enrolled patients (figure 1). In addition, the
proportion of PCP diagnosed in PE group among all PCP
diagnosis has remained stable during the study period (46% in
2004 vs. 40% in 2010, Cochran Armitage test for trend p = 0.77).
Characteristics of the patients
Over our study period a first episode of PCP was diagnosed in
1488 patients, of whom 1259 patients with at least a CD4 cell
count within 3 months of PCP diagnosis and at least one CD4 cell
count during follow-up were retained for analysis (figure 2).
The patients’ characteristics at PCP diagnosis are shown in
table 1. Overall, 593 (47%) patients were previously enrolled in the
FHDH. The majority of patients were males (73%). Median age
was 42 years (IQR, 36–49). Migrants represented 12% of the
overall population, and sub-Saharan patients were more numer-
ous among patients with a PCP revealing HIV infection. The IDU
HIV transmission group was more numerous in the PE group.
The median CD4 cell count and median viral load at PCP
diagnosis were 38/mm3 (IQR, 15–92) and 5.2 log10 copies/ml
(IQR, 4.6–5.7), respectively, with no difference of clinical
importance between PE patients, and patients in the reference
group.
For PE patients, median time since enrolment was 8.2 years
(IQR, 3.7–11.3) and 27% of them had had a prior ADI. Although
439 (74%) of these patients had already had a prescription for
cART, all but 18 of them had detectable VL at PCP diagnosis
(median, 5 log10 copies/ml [IQR, 4.1–5.6]). Among PE patients
with at least one year of cART prescription before PCP, 277 (69%)
patients have had at least once high CD4 cell count (CD4 cell
count.350/mm3), and 318 (80%) patients a virological response
(HIV viral load,500 copies/ml). Median proportion of time with
adequate adherence to care was 60% (IQR, 33–84) since FHDH
enrolment for PE patients until PCP diagnosis, and 45% (IQR, 1–
81) during the 2 years before PCP diagnosis, compared to a
median proportion of 85% (IQR, 66–96) for all FHDH enrollees.
Figure 2. Patient selection flow diagram.
doi:10.1371/journal.pone.0094183.g002
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Table 1. Patients with a first episode of PCP in 2004–2011: characteristics at PCP diagnosis.
Previously Enrolled
patients with an
incident PCP
Previously Enrolled
patients with an incident
PCP without prior ADI
Previously Enrolled
patients with an incident
PCP with prior ADI
Patients with an
inaugural PCP
revealing HIV infection P value6
(all PE) (PE non-prior ADI) (PE prior ADI) (reference)
Total 593 (100%) 432 (100%) 161 (100%) 666 (100%)
Male gender 417 (70%) 293 (68%) 124 (77%) 502 (75%) 0.001
Age (years) 42 (37–47) 42 (37–47) 42 (38–48) 42 (36–50) 0.55
Sub-Saharan origin 50 (8%) 32 (7%) 18 (11%) 103 (15%) 0.0003
Transmission group ,0.0001
MSM 154 (26%) 116 (27%) 38 (24%) 189 (28%)
IDU 109 (18%) 68 (16%) 41 (25%) 20 (3%)
Heterosexual 330 (56%) 248 (57%) 82 (51%) 457(69%)
CD4/mm3 38 (15, 92) 53 (18,140) 33 (10,99) 34 (13,70) ,0.0001
HIV viral load, log10
copies/ml (N = 1169)
5.2 (4.6,5.7) 5.1 (4.1, 5.6) 5.0 (3.3, 5.6) 5.3 (4.8, 5.7) ,0.0001
Time since enrolment (years) 8.2 (3.7, 11.3) 8 (3.7,11.1) 8.7 (3.8,11.7) NA
cART .1year 400 (68%) 262 (61%) 138 (86%) NA
Patients with cART .1 year
Duration of treatment (years) 7 (4.8–9) 6.7 (4.6, 8.8) 7.8 (5.1, 8.8) NA
CD4 nadir up to cART initiation 180 (81–300) 204 (106, 324) 119 (36, 220) NA
CD4.350/mm3 * 277 (69%) 191 (73%) 86 (62%) NA
HIV viral load ,500 copies/ml ** 318 (80%) 203 (77%) 115 (83%) NA
Figures are medians (Interquartile Range) or N (%); uP value: x2 test for categorical variables and Kruskal-Wallis test for continuous variables, comparison between PE
non-prior ADI, PE prior ADI, and reference groups.
* Percentage of patients with CD4 cell count .350/mm3 after cART initiation;
**percentage of patients with HIV viral load,500 copies/ml after cART initiation ADI: AIDS-defining illness, MSM: Men who have Sex with Men, IDU: Intravenous Drug
User.
doi:10.1371/journal.pone.0094183.t001
Figure 3. Kaplan-Meier estimates of immune reconstitution (CD4 cell count$200/mm3) probability, and number of patients at risk,
after PCP diagnosis for patients with an inaugural PCP revealing HIV infection (reference, group 1), previously enrolled patients
with incident PCP without prior AIDS-defining clinical illness (ADI) (PE non-prior ADI, group 2) and previously enrolled patients
with incident PCP with prior ADI (PE prior ADI, group3).
doi:10.1371/journal.pone.0094183.g003
Pneumocystis Pneumonia in cART Era
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Virological, immunological and clinical outcomes
One year after PCP diagnosis, VL was #50 copies/ml in 64%
of PE non-prior ADI patients, 49% of PE prior ADI patients and
76% of patients in the reference group (p,0.0001). Among the
1145 patients (91%) with CD4 cell counts below 200/mm3 at PCP
diagnosis, 52% had CD4 cell counts $200/mm3 one year after
PCP diagnosis, and 84% at three years. At 1 and 3 years,
respectively, CD4 cell counts $200/mm3 were achieved in 48%
and 78% of PE non- prior ADI patients, and 29% and 68% of PE
prior ADI patients and 58% and 90% of patients in the reference
group (figure 3). PE non-prior ADI patients (HR, 0.7 [95%CI,
0.6–0.8]) and PE prior ADI patients (HR, 0.6 [95%CI, 0.4–0.8])
had slower immune reconstitution than patients in the reference
group (table 2).
Mortality at 1, and 3, years after PCP diagnosis was 7%, and
11%, respectively. In subgroup analyses, mortality at 1 and 3 years
was respectively 5% and 8% among PE non-prior ADI patients,
16% and 25% among PE prior ADI patients and 6% and 9%
among patients in the reference group (p,0.0001). After
adjustment on baseline characteristics, PE prior ADI patients
were at increased risk of mortality (HR, 2.7 [95%CI, 1.7–4.2])
compared to patients in the reference group (Table 3). This higher
mortality risk for PE prior ADI patients remained after adjustment
on viral suppression and immune reconstitution (HR, 2.4 [95%CI,
1.5–3.7]).
Discussion
In a context of a decreasing risk of PCP, 47% of patients
diagnosed with PCP have already been in care but presented a
poor adherence to care during the 2 years prior to PCP diagnosis.
In addition, the 3 year mortality rate after PCP diagnosis was very
high (25%) for previously enrolled patients with prior ADI, higher
than in previously enrolled patients without prior ADI and the
reference group of patients with an inaugural PCP revealing HIV
infection.
This is the largest observational study of PCP in the recent
cART era; however several limitations must be discussed. First, we
used PCP diagnoses and deaths reported in the FHDH cohort. A
previous analysis of this cohort showed that 93% of PCP diagnoses
were confirmed on examining the patients’ clinical records [15].
Second, among 1488 patients with a first episode of PCP during
the study period, 229 patients were excluded from this analysis
because of a lack of CD4 cell counts at PCP diagnosis or during
Table 2. Factors associated with immune reconstitution (CD4.200/mm3) within 3 years after PCP.
Total
Nb of events within
3 years after PCP
Univariate
analysis
Adjusted
analysis P value
HR* (95%CI) HR* (95%CI)
Patient group ,0.0001
Reference group with inaugural PCP 640 468 1.0 1.0
PE non-prior ADI patients 368 236 0.7 [0.6–0.8] 0.7 [0.6–0.9]
PE prior ADI patients 137 63 0.4 [0.3–0.6] 0.6 [0.4–0.8]
Age (years] 0.62
,30 93 60 1.0 [0.8–1.3] 1.1 [0.8–1.4]
[30–49] 802 540 1 1
$50 250 167 1.2[1.0–1.4] 1.1 [0.9–1.3]
Transmission group 0.001
MSM 308 230 1.3 [1.2–1.6] 1.1 [0.9–1.3]
Heterosexual 724 481 1 1
IDU 113 56 0.6 [0.5–0.8] 0.6 [0.5–0.8]
Origin 0.0002
Sub-Saharan 146 78 1 1
Other 999 689 1.7 [1.3–2.1] 1.6 [1.2–2.1]
CD4 at PCP diagnosis (/mm3] ,0.0001
[0–49] 718 439 1 1
[50–99] 245 181 2.0 [1.7–2.4] 2.2 [1.8–2.6]
[100–199] 182 767 2.6 [2.1–3.1] 3.1 [2.6–3.9]
HIV viral load (VL) at PCP diagnosis ,0.0001
,5 log10 copies/ml 405 256 1 1
$5 log10 copies/ml 662 468 1.3 [1.1–1.5] 1.4 [1.2–1.7]
HIV VL#50 copies/ml after PCP (time-dependent
covariable)
,0.0001
No NA NA 1 1
Yes NA NA 2. 3 [1.9–2.9] 2.3 [1.8–2.8]
*Adjusted HR.1: in favor of achieving a CD4 cell count $200/mm3; PE non prior ADI: previously enrolled patients without prior AIDS-defining illness, PE prior ADI:
previously enrolled patients with prior AIDS-defining illness, MSM: Men who have Sex with Men, IDU: Intravenous Drug User.
doi:10.1371/journal.pone.0094183.t002
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subsequent follow-up. No excess mortality was observed in this
patient subgroup (data not shown). Third, the rate of loss to follow
up at 3 years after PCP was 16%. But owing to the French law that
prevents nominative or indirectly nominative data collection in
FHDH; vital status could not be checked against the national
death registry. However no difference in rate of loss of follow-up
was observed between the 3 groups (Log Rank test p = 0.74).
In previous studies of PCP few patients had been prescribed
cART before PCP onset [6–8] but an increase of the proportion of
ADI and specifically of PCP have been recently reported in
pretreated HIV infected patients followed up in industrialized
countries despite free access to care [12,13]. In our study, among
previously enrolled patients, 2/3 had had at least a cART
prescription for more than one year before PCP. Before PCP, 67%
of patients with at least one year of cART prescription have had
an immunological response and 80% a virological response;
theoretically those patients should not have presented a PCP
episode. Since all PE patients had very low CD4 cell count and
high VL at PCP diagnosis, it could be hypothesized that for some
patients, adherence had diminished over time with a risk of
developing ADI. Patients are now facing the challenge of life-long
adherence to medications and care and our policy must evolve.
Efforts have been focused on adherence at the beginning of cART.
We need now to concentrate on patients followed up for many
years and design interventions to lower the risk of decreasing
adherence over time.
It was striking to note that PE patients (with and without prior
ADI) had a worse immune reconstitution than the reference
group. CD4-nadir before cART initiation has been shown as the
strongest predictor of the immune response [16,17]. The extent of
prior CD4 T cell depletion determined the size of the viral
reservoir after prolonged suppressive antiretroviral therapy [18].
In our study, PE prior ADI patients have had a lower CD4 nadir
at cART initiation (median of CD4: 119/mm3 (IQR, 36–220))
compared to PE non-prior ADI patients, (median of CD4: 204/
mm3 (IQR, 106–324)). This could explain the difference of
immune reconstitution after PCP between these two groups of
patients. The role of antiretroviral drug resistance could also be
hypothesized to explain that previously enrolled patients had a
lower rate of immune reconstitution than patients with PCP
revealing HIV. The time required to reach a CD4 cell count
above 300/mm3 has been shown to increase with the number of
failed regimens [19].
Despite cART, having an ADI like PCP is still associated with a
poor vital prognosis. Overall, in the last fifteen years, the 3-year
post-PCP mortality rate have not changed in the FHDH cohort
from 12% in 1998–2000 [1] to 11% in the present study.
However, a special group of patients with very high mortality
(25%, PE prior ADI patients), was identified in our study, probably
explaining why the overall mortality rate has not fallen. Since IDU
were more numerous in PE prior ADI patients, a sensitivity
analysis was undertaken in order to see if part of the poor
prognosis could be explained by non-AIDS cause of death such as
overdose. In this sensitivity analysis excluding the IDU group, an
increase of risk of death was still observed for PE prior ADI
patients (HR = 2.6 [1.6–4.3]).
Patients in the PE prior ADI group who presented with another
ADI, here PCP, had a poorer prognosis that persisted after
adjusting on baseline characteristics and on immune reconstitution
and viral suppression. HIV viral load and CD4 cell counts are
strong predictors of the risk of death but having repeated ADI is
contributing to the risk of death beyond its impact on immune
reconstitution and viral suppression. This is in line with the results
of a large collaborative European study that showed a persistent
role of prior AIDS on the risk of death, even in patients with CD4
cell counts $500/mm3 [20]. One hypothesis may be an immune
system dysfunction not exclusively translated in the CD4 cell count
which could deepen at each ADI. Clinicians must be aware of the
pejorative effect of an ADI even at a time where powerful
treatments are available. Warning message on importance of
maintaining viral suppression and immune reconstitution to
prevent any new ADI must be regularly reinforced and especially
for patients with a previous ADI.
Conclusion
In a context of diminishing risk of PCP, half of the patients
diagnosed with PCP in the recent cART period were already in
care; the majority of them had already started cART but with
vanishing adherence to care. Efforts need to be stressed on those
patients with a history of previous ADI in order to prevent further
event which will increase mortality. The consequences of having
had an ADI need to be explained to patients as well as the
necessity of maintaining an excellent observance and never stop
cART.
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